Tepotinib

Search with Google Search with Bing

Information
Drug Name
Tepotinib
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung non-small cell carcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION B Predictive Supports Sensitivity/Response Somatic 3 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
In a interim analysis of Phase II trial for MET ex... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02864992 Active, not recruiting Phase 2 Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) September 13, 2016 February 20, 2025
NCT03940703 Active, not recruiting Phase 2 A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) September 19, 2019 May 27, 2024
NCT04591431 Active, not recruiting Phase 2 The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy October 7, 2020 June 2025
NCT01982955 Completed Phase 1/Phase 2 Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) December 23, 2013 October 14, 2021
NCT03492437 Completed Phase 1 Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate May 17, 2018 August 27, 2018
NCT03531762 Completed Phase 1 Effect of a Proton Pump Inhibitor on the PK of Tepotinib May 14, 2018 July 2, 2018
NCT03546608 Completed Phase 1 Tepotinib Hepatic Impairment Trial June 13, 2018 February 5, 2019
NCT03628339 Completed Phase 1 Effect of Tepotinib on PK of CYP3A Substrate Midazolam August 20, 2018 October 30, 2018
NCT05213481 Completed Phase 1 Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants December 15, 2021 May 6, 2022
NCT01988493 Completed Phase 1/Phase 2 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma January 6, 2014 December 3, 2020
NCT02115373 Completed Phase 1/Phase 2 c-Met Second-Line Hepatocellular Carcinoma May 18, 2014 February 14, 2018
NCT06106802 Not yet recruiting Phase 2 Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment February 2, 2024 September 30, 2029
NCT06031688 Not yet recruiting Phase 2 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) July 15, 2024 May 31, 2029
NCT06083857 Not yet recruiting Phase 1/Phase 2 PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer April 30, 2024 December 31, 2027
NCT05782361 Recruiting Phase 1 POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC May 3, 2023 February 1, 2028
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT04647838 Recruiting Phase 2 Tepotinib in Solid Tumors Harboring MET Alterations January 16, 2020 August 31, 2024
NCT04515394 Terminated Phase 2 Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) January 28, 2021 March 31, 2022
NCT04739358 Terminated Phase 1/Phase 2 CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC May 25, 2022 June 23, 2023
NCT05120960 Withdrawn Phase 1 A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors February 27, 2023 April 12, 2024